勘误：实体瘤中的嵌合抗原受体T细胞疗法：挑战与临床应用
Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
作者信息
Mirzaei Hamid R, Rodriguez Analiz, Shepphird Jennifer, Brown Christine E, Badie Behnam
机构信息
Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States.
出版信息
Front Immunol. 2019 Apr 17;10:780. doi: 10.3389/fimmu.2019.00780. eCollection 2019.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2017.01850.].
摘要
[本文更正了文章DOI：10.3389/fimmu.2017.01850。]
相似文献
1
Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.勘误：实体瘤中的嵌合抗原受体T细胞疗法：挑战与临床应用
Front Immunol. 2019 Apr 17;10:780. doi: 10.3389/fimmu.2019.00780. eCollection 2019.
2
Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.勘误：细胞治疗中的淋巴细胞：CAR-T细胞的功能调节
Front Immunol. 2019 Mar 8;10:401. doi: 10.3389/fimmu.2019.00401. eCollection 2019.
3
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.实体瘤中的嵌合抗原受体T细胞疗法：挑战与临床应用
Front Immunol. 2017 Dec 22;8:1850. doi: 10.3389/fimmu.2017.01850. eCollection 2017.
4
Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.勘误：胆管癌、胰腺癌和胃癌中CAR T细胞疗法的进展
Front Immunol. 2022 Dec 20;13:1082984. doi: 10.3389/fimmu.2022.1082984. eCollection 2022.
5
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.嵌合抗原受体 T 细胞疗法在实体瘤中的挑战与展望。
Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.
6
[Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].[嵌合抗原受体工程化T细胞免疫疗法治疗实体瘤的前景]
Zhonghua Zhong Liu Za Zhi. 2018 Jul 23;40(7):490-492. doi: 10.3760/cma.j.issn.0253-3766.2018.07.002.
7
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.嵌合抗原受体修饰的 T 细胞治疗肝癌。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24.
8
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.勘误：在滤泡性淋巴瘤患者接受嵌合抗原受体T细胞治疗后，通过可追踪突变的特定特征对循环肿瘤DNA进行个性化监测。
Front Immunol. 2023 Aug 16;14:1243241. doi: 10.3389/fimmu.2023.1243241. eCollection 2023.
9
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.勘误：在滤泡性淋巴瘤患者接受嵌合抗原受体T细胞治疗后，通过可追踪突变的特定特征对循环肿瘤DNA进行个性化监测。
Front Immunol. 2024 Jan 10;14:1349296. doi: 10.3389/fimmu.2023.1349296. eCollection 2023.
10
Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments.勘误：基于配体的嵌合抗原受体T细胞：未来新疗法中驱动T细胞的不同策略。
Front Immunol. 2022 Nov 21;13:1078003. doi: 10.3389/fimmu.2022.1078003. eCollection 2022.
引用本文的文献
1
Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).前沿基因组编辑技术在人类疾病治疗中的应用：CRISPR 疗法（综述）。
Int J Mol Med. 2020 Aug;46(2):521-534. doi: 10.3892/ijmm.2020.4609. Epub 2020 May 19.
2
B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.靶向B7-H3的嵌合抗原受体T细胞对血液系统肿瘤和实体瘤显示出强大的抗肿瘤作用。
Mol Ther Oncolytics. 2020 Apr 7;17:180-189. doi: 10.1016/j.omto.2020.03.019. eCollection 2020 Jun 26.
Zotero 插件